http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013201228-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fe79f6eb1e709dbf956eaeaccc1c540 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2013-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2dedc93528351a244b0b853b34a0d9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_890f9ab63548b2943eac281aa0aa7e1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8c7d78e1a0d0e3cfdb18a6ec0699fef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_440ae482fdbdf11f834918e151585f9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b1959dd54b6face64b2d055bcaa1b02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c03f45320d3364880724490d57eeb2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c8d076d43ba4c46fcfb7702559563ba |
| publicationDate | 2016-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013201228-B2 |
| titleOfInvention | Antigenic gm-csf peptides and antibodies to gm-csf |
| abstract | An isolated human monoclonal antibody that specifically binds to an epitope of granulocyte-macrophage colony stimulating factor (GM-CSF), said epitope comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO:37, SEQ ID NO:38, and SEQ ID NO:39. The invention also provides a method for treating a granulocyte-macrophage colony stimulating factor (GM-CSF)-mediated cancer in a subject in need thereof, said method comprising administering to the subject a composition, said composition comprising a pharmaceutically acceptable carrier and a human monoclonal antibody that specifically binds to the above epitope of GM-CSF. Also disclosed is a method for treating granulocyte-macrophage colony stimulating factor (GM-CSF)-mediated cancer in a subject in need thereof which comprises administering a pharmaceutically acceptable carrier and a human monoclonal antibody produced by a cell deposited as ATCC Accession No. PTA-8173 that binds to GM-CSF, in an amount effective to treat GM-CSF-mediated cancer. Figure 1 S IL-1 EIL-2 IL-3 1 L-4 3.5 _ il IL-5 El I L-6 M IL-1 3 E TT ElhGM-CSF E mGM-CSF 0 BSA 0.5 -- el <; %9 |
| priorityDate | 2006-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1012.